Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

K-Group Beta Inc.
Sponsor

K-Group Beta Inc.

United States 10275 Science Center Drive Suite 200, 92121-1170, United States

About the sponsor

Research activity includes high-grade serous ovarian cancer, platinum-resistant ovarian cancer, and primary peritoneal cancer, with attention to treatment-resistant disease and antitumor activity in women with advanced gynecologic cancers.

  • High-grade serous ovarian cancer
  • Platinum-resistant ovarian cancer
  • Primary peritoneal cancer

These programs focus on recurrent and persistent disease settings where new therapeutic options are needed.

About Specializations

K-Group Beta Inc. runs clinical trials in conditions such as Malignant peritoneal neoplasm, Fallopian tube cancer, Ovarian cancer, Ovarian cancer recurrent, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Malignant peritoneal neoplasm+2

Recruiting

Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:K-Group Beta Inc.

Malignant peritoneal neoplasm+2

Not yet recruiting

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Ovarian cancer recurrent

Not recruiting

Study of Azenosertib and Niraparib for Patients with Platinum-Resistant Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Papillary serous endometrial carcinoma

Not recruiting

Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:K-Group Beta Inc.

Colorectal cancer metastatic

Not recruiting

Study of ZN-c3, Encorafenib, and Cetuximab for Adults with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.